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ABSTRACT 
     Celiac disease (CD) is an immune-mediated disorder resulting in nutrient malabsorption now thought to 
have a prevalence of 1:100 in the Iranian population. 
Symptoms of CD are included diarrhea, abdominal pain, steatorrhea, bloating, cramps, flatulence, weight 
loss, weakness and short stature. In addition to presenting symptoms, patients are also at increased risk of 
metabolic bone disease, lymphoma (enteropathy-associated with T-cell) and other malignancies in different 
parts of the body such as gastric, esophageal, bladder, breast and brain. There appears to be a strong genetic 
component to this disease. In this short review we provided the historical, clinical and genetic aspects of this 
disease and highlight numerous findings from recent molecular immunology studies. 
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INTRODUCTION 
     Until recently, CD was considered a 
comparatively uncommon disorder, with a 
prevalence rate quoted as 1 in 1000 or lower and 
considered a disease of essentially European 
origin but now thought to have a prevalence of 
between 1:100 to 1:200 in Europe as well as 
Iranian population [1]. CD develops as a result 
of an interaction between genetic, 
environmental, and immunological factors. The 
clinical presentation of CD is highly variable and 
ranged from typical symptoms include diarrhea, 
steatorrhea, bloating, Osteoporosis, anemia, 
vomiting, delayed puberty, flatulence, weight 
loss and fatigue to atypical symptoms included 
abdominal pain, dyspepsia, infertility, 
neurological disorders and constipation [2].  
In addition to the incidence of presenting 
symptoms, celiac patients are also at increased 
risk of osteoporosis, non-Hodgkin and 
enteropathy associated T-cell lymphomas (NHL 
and EATL) and other malignancies [3]. Celiac 
disease also is an association with a variety of 
diseases with an autoimmune etiology such as 
autoimmune cholangitis, hepatitis, myocarditis, 
neuropathy dermatitis herpetiformis,  primary 
biliary cirrhosis, Down’s syndrome, sarcoidosis, 
epilepsy, Sjogren’s syndrome, diabetes mellitus 
type I and, thyroid disease [4-14]. 
Celiac disease may develop in only genetically 
susceptible individuals. The strongest genetic 
factor that is associated with CD is human 
leukocyte antigen (HLA)-DQ2 and -DQ8 and is 
found in virtually all CD patients and the 
absence of HLA-DQ2 or -DQ8 virtually 
excludes the diagnosis of CD [15].   
In this review I investigated the recent 
immunological, genetic and molecular evidence 
from the literature to suggest a mechanism 
underlying the pathophysiology of this disease.  
 
Gene Identification in Celiac Disease 
      Genetic linkage and genetic association 
studies are complementary advances which used 
in the search for genetic susceptibility genes in 
CD. Genetic linkage studies make use of families 
with affected sibling pairs to identify 
chromosomal regions shared between the 
affected siblings above the mean of what is 
statistically expected (Figure 1). Linkage regions 
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usually encompass 10 to 100 genes. Once 
linkage is identified, the next step is a genetic 
association study to identify the specific disease 
gene from the candidate gene locus [16]. 
Candidate gene association studies search for 
differences in the frequencies of genetic variants 
in patients compared to control individuals. Such 
association studies can focus on positional 
candidate genes from a linkage region, or on 
functional candidate genes selected from 
Hypothesized disease pathology [17]. More 
recently, it has become feasible to perform 
genome wide association studies which can test 




Figure 1. Distribution of the MLS scores for 
chromosome 6. 
 
Native Immunity Correlates with Celiac 
Disease  
      Different investigators cleared the role of 
HLA-DQ2 in the pathogenesis of CD, but none 
of them deal with why wheat is a harmless food 
in most people with HLA-DQ2 or HLA-DQ8 
[18, 19]. Since the immunogenic gluten epitopes 
to the adaptive immune system in a pro-
inflammatory circumstance released; therefore, 
the lack of immunological tolerance to gluten 
can be understood. Any loss of the entirety of 
gut epithelium would allow the activation of the 
resident immune system to any “nonself” 
antigens leaking in from the gut lumen [19]. 
The identification of the triggers for loss of 
epithelial cells is related to the presence of 
gluten antigens in the lamina propria, and the 
beginning of HLA-DQ2/DQ8-restricted adaptive 
immune response.  
Undoubtedly the key to explaining the presence 
of gluten antigens in the lamina propria, and the 
initiation of the HLA-DQ2 and/or -DQ8-
restricted adaptive immune response, is then to 
identify the trigger for such a loss of epithelial 
integrity. 
Hue et al. in 2004 showed that toxic p31–49 
peptide induced the term of the atypical MHC 
molecule MICA on the cell surface of the villus 
epithelium in treating celiac patients but not 
general controls [20]. Also high levels of MICA 
surface expression detected in untreated celiac 
patients and that the surface levels appeared to 
associate with the clinical severity of disease. 
MICA is induced by cellular stress and serves as 
a ligand for the NKG2D receptor. The NKG2D 
receptor is found on the surface of CD8+ αβ T 
cells, γδ T cells and most NK cells [21]. 
Compatible to these findings Meresse et al. 
demonstrated that resident intraepithelial 
lymphocytes in the small intestine of celiac 
patients are capable of lysing epithelial cells 
solely through the NKG2D-MICA interaction 
and express the NKG2D receptor [22].  
 
Genetics of Coeliac Disease 
    The higher prevalence of CD in sibs of CD 
patients has shown in several studies compared 
with the general population [23, 24]. 
In Bourgey et al. Study CD status was 
determined and HLADQ genotyping performed 
in the cohort of 188 Italian families with CD. 
The result of this study showed the overall risk a 
sib of a CD patient will develop the disease was 
estimated at 10%. These results make it possible 
to provide more accurate information to parents 
with a child with CD about the real risk for 
another child [2].  
Genetic component was found in around 87% of 
a large cohort of 73 Italian twins with at least 
one affected with CD [25]. As expected, 
concordance rates were significantly observed in 
monozygotic than dizygotic twins with an 
adjusted hazard ratio for developing CD in those 
with an affected monozygotic twin of 14.3%.  
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Fasano et al. screened 13 145 people using 
modern serology techniques and 
histopathological biopsy confirmation in a large-
scale multicentre study in the USA [26]. The 
result of this study showed that the prevalence of 
CD in first-degree relatives was 1:22, in second-
degree relatives was 1:39 and in symptomatic 
patients was 1:56. The overall risk for 
individuals without these risk factors was 1:133. 
Celiac disease susceptibility has been strongly 
associated with HLA-DQ2 and HLA-DQ8. The 
HLA DQ2 (DQA1*05/DQB1*02) heterodimer is 
present in approximately 95% of patients 
with CD, and the remaining patients (5–10%) 
have HLA-DQ8 (DQA1*0301/DQB1*0302). 
HLA-DQ2 is common in Europeans and is 
expressed by 25-30% of the normal European 
population. Consequently, the estimated HLA 
contribution to the development of the CD is 
estimated to be approx. 35% [27-35]. Most of the 
CD patients who do not carry DQ2.5 or DQ8, 
suggesting that carrying part of the risk 
molecules has functional implications for the 
risk of CD [35]. 
The lack of these alleles has a high negative 
predictive value in general and therefore, HLA-
DQ2 and/or DQ8 are best thought of as 
necessary but not sufficient for the development 
of celiac disease. 
Several studies on Iranian population healthy 
population using PCR/RFLP method in different 
parts of Iran show that the most common 
haplotype in different ethnic groups like Turk, 
Kurd, Lur, Arab, Turkmen and Baloch is DQ7 
and DQ2 [36-39] (table 1).  
 
Table 1. HLA-DRB1, DQA1, and DQB1 allele and 
haplotypes frequencies in different ethics of Iran 












Kurd B1*1103/04 *0501 *0301 DRB1*1103/04-
DQA1*0501-
DQB1*0301 
Azari B1*1103/04 *0501 *0301 DRB1*1103/04-
DQA1*0501-
DQB1*0301 









Zoroastrian B1*0701 *0501 *0201 DRB1*0701-
DQA1*0201-
DQB1*0201 
These results conducted significant similarities 
in HLA class II haplotype distributions with 
European countries. 
These days diverse techniques are carried out to 
detect the HLA risk alleles in different 
populations. Koskinen et al. [35] and Monsuur et 
al. [36] used tagging single nucleotide 
polymorphisms (SNPs) method for detecting the 
HLA risk alleles. The results of showed that the 
sensitivity and specificity of HLA-SNP to 
recognize DQ2.2, DQ2.5, DQ7, and DQ8 
haplotypes in the different European population 
was higher than >98% (figure 2). Also using this 
method Rostami Nejad et al. evaluate the 
distribution of HLA DQ2 and DQ8 in Iranian 
CD patients compared to healthy controls [41]. 
The results of this study showed that the 
frequency of DQ2 was higher in CD patients 
than controls and also the prevalence of DQ8 




Figure 2. Genetic risk associated with the different 
HLA-DQ molecules. 
HLA-DQA1* and -DQB1* together form heterodimers 
of which DQ2.5 and DQ8, either in homozygous or 
heterozygous state, confer risk to CD due to their ability 
to present gluten to T cells. DQ2.2 and DQ7 can only 
confer risk to CD when both are present together or with 
DQ2.5 (trans effect). Patients who carry DQ7 haplotype 
are low risk for CD, an intermediate risk if they were 
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homozygous for HLA-DQ2.2, DQ8, heterozygous for 
DQ2.5 or for DQ2.2, a high risk for those homozygous 
for DQ2.5and DQ2.5/DQ2.2 
Trynka et al. in their large sample collection 
study genotyped 183 non-HLA risk loci in 
12,041 patients with celiac disease and 12,228 
controls using variables from the 1000 Genomes 
Project pilot European dataset [42]. They 
identified 13 new CD risk loci and found 
multiple independent association signals at over 
one-third of these loci. In particular, 29 of the 54 
fine-mapped signals seemed to be localized to 
single genes and, in some instances, to gene 
regulatory elements.  
During 2010, 27 seronegarive children with 
celiac disease and 9 of their brothers were 
evaluated by PCR, DQ2/DQ8 haplotypes [43]. 
The result of this investigation confirmed the 
diagnosis of CD in 22 children and 7 of their 
brothers. The outcome of this study is underlying 
the importance of the genetic testing in 
seronegative patients and also in identifying 
family risk for people with celiac disease. 
CONCLUSION  
     Celiac disease is a genetically determined 
pathological condition associated with HLA 
genes that code for the DQ2 and DQ8 molecules. 
Various studied suggested that the HLA-
DQB1*02 allele (coding HLA DQ2) in addition 
to having an important role in the predilection of 
the CD, also it is in contribution with the 
severity of the intestinal mucosa damage [44-
48]. 
Based on these findings, Biagi et al. reported that 
patients with homozygous for HLA DQ2 not 
only have more severe clinical symptoms, also 
develop more severe intestinal lesions than is 
normally observed which take longer to heal 
after gluten free diet [49].  
The previous studies confirmed that HLA-DQ 
genes code for proteins responsible for the 
histologic, immunological, and clinical 
heterogeneity of the celiac disease [50, 51]. In 
contrast, even if there is a correlation between 
the risk of CD and the dose of the DQB1*02 
allele, it is certainly not possible to predict 
whether and when these patients will develop the 
disease, if there is any risk of complications and 
if the degree of mucosal atrophy will be more 
severe. Also we should attention to this point 
that this condition depending on environmental 
factors such as the time of exposure to gluten 
and the patient’s compliance to a gluten-free 
diet. 
Rashtak, Murray in 2007 suggests that when 
there is a high suspicion of CD, HLA typing is a 
high-sensitivity rule-out test and when the 
probability is low serological testing is a high-
specific rule-in test [50]. This strategy might be 
helpful in encouraging health professionals to 
use serology because the index of suspicion is 
generally low for atypical presentations [2]. In 
contrast, using serology alone might result in 
missing those patients with negative serology 
even when the suspicion is low [52-54]. Perhaps 
performing HLA typing in seronegatives would 
give some more degree of reassurance in ruling it 
out and finally I suggest that the performance of 
readily available serological tests in combination 
with the genetic risk study, significantly reduce 
the burden of celiac disease in at risk population.  
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